Palla Pharma Ltd (PAL) is an independently owned company that manufactures Narcotic Raw Material (NRM), Active Pharmaceuticals Ingredients (API) and Finished Dosage form Products (FDF).
Founded in 2004 as TPI and rebranded in 2019. Palla Pharma has grown into a forward-thinking and innovative company that has earned an international reputation for the high quality of its product and competitive pricing.
Palla Pharma is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of six licensed NRM producers globally and one of only three fully integrated suppliers of opiates from NRM, API through to FDF products. The Company’s expansion within Australia and Europe includes the introduction of new growing areas to ensure long term sustainability for the supply of raw materials to meet our customer’s requirements. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process. We have adopted industry best practice across every facet of our operations.
Palla Pharma’s experienced and highly skilled team provides the Company with its greatest commercial advantage, drawing on extensive industry and commercial experience.
Forging strong relationships is at the heart of Palla Pharma's business philosophy. From the farmer to customer delivery, our team understands the value of maintaining a more personal approach to the partnerships we foster. We deliver a highly competitive pricing platform made possible by our innovative growing and manufacturing practices.
Palla Pharma is a global business with our Australian operations in Victoria and Tasmania; and our northern hemisphere office based in Norway.
We source our raw materials from Australian poppy growers in Victoria, New South Wales, and Tasmania; and are developing new grower relationships in Europe as part of our international expansion.
Board of Directors
Jarrod Ritchie BSc (Hons)
Managing Director / Executive Director
Jarrod Ritchie has over 20 years’ experience in the opiates industry. He has led Palla Pharma from its inception as a start-up to its current position as Australia’s third licensed poppy processor with a strong international reputation. Jarrod has led new research in the opiates industry including Palla Pharma's unique, environmentally-sustainable, solvent-free manufacturing process. He has also led the successful trialling of a new thebaine-rich variety of poppy; the introduction of commercial crops to Victoria and New South Wales ;the trialling of poppy crops in the Northern Territory; and the expansion of Palla Pharma's global operations.
Simon Moore is a Non-Executive Director of ASX-listed Megaport, a Non-Executive Director of ASX-listed Firstwave Cloud Technology Limited, a Non-Executive Director of Mexican fast casual restaurant chain Guzman Y Gomez and a Non-Executive Director of venture capital firm, OneVentures.
Simon was previously a Managing Director of The Carlyle Group, and prior to that was a Managing Director and Investment Committee Member of Investcorp International, Inc. based in New York. Prior to that he worked in private equity investments and investment banking at J.P. Morgan & Co. in New York, Hong Kong and Melbourne. Simon’s personal investments include significant pastoral holdings and investments in a number of agricultural enterprises.
Todd Barlow is the Managing Director and CEO of Washington H. Soul Pattinson and Company Limited and a Non-Executive Director of ASX listed New Hope Corporation Limited. Before joining Washington H. Soul Pattinson, he was Managing Director of Pitt Capital Partners Limited, a Sydney based corporate advisory firm. He continues to serve as a non-executive director of Pitt Capital Partners Limited as well as a number of unlisted entities.
Between 2005 and 2008 Todd was based in Hong Kong, and provided advice on cross-border transactions between Asia and Australia. He previously practiced as a lawyer, specialising in corporate law and mergers and acquisitions.
Independent non-executive Director
Stuart Black is a Chartered Accountant with extensive experience in agribusiness. He retired in 2013 as managing partner of a practice specialising in agribusiness. Stuart is a current non-executive director of Australian Agricultural Company Limited, NetComm Wireless Limited, and a Past President of the Institute of Chartered Accountants of Australia. He was the inaugural Chair and a past board member of the Accounting Professional and Ethical Standards Board and served as the Australian representative on the International Federation of Accountants SMP Committee. Stuart is Chair of the Chartered Accountants Benevolent Fund Limited and a Director of the Country Education Foundation of Australia Limited.
In 2012 Stuart was appointed a Member of the Order of Australia for services to the profession of accounting, to ethical standards, as a contributor to professional organisations and to the community.
Sue MacLeman has more than 30 years’ experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development. Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the pharmaceutical sector and is currently Chair of Anatara Lifesciences Ltd (ASX:ANR), Chair of Novita Healthcare Ltd (ASX:NHL), Chair and Non-Executive Director of MTPConnect (MTPII-GC Ltd), Non-Executive Director of Oventus Medical Ltd (ASX:OVN) and Non-Executive Director of veski.
Sue is also appointed to several academic and government advisory committees. Her broad commercial experience is underpinned by graduate qualifications in pharmacy and post graduate qualifications in commercial law, corporate governance, business administration and marketing.
Palla Pharma operates and manages the company’s Australian operations.